Thromboembolism Clinical Trial
Official title:
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.
The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic venous thromboembolism (VTE), following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. This trial aims to demonstrate non-inferiority of dabigatran compared with warfarin in patients with acute symptomatic VTE. After achieving non-inferiority, this trial also aims to establish superiority (by means of hierarchical tests) of dabigatran over warfarin.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
| Active, not recruiting |
NCT05563883 -
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
|
||
| Terminated |
NCT02475187 -
Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
|
||
| Recruiting |
NCT00982514 -
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
|
N/A | |
| Completed |
NCT01420809 -
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
|
N/A | |
| Terminated |
NCT00206089 -
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
|
Phase 3 | |
| Completed |
NCT00014352 -
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
| Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
| Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
| Completed |
NCT02935751 -
Apixaban Discontinuation Prior to Major Surgery
|
||
| Terminated |
NCT02579122 -
REVIparin-BRIDging-in a General Practice Setting in GErmany
|
||
| Completed |
NCT01696760 -
Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
|
N/A | |
| Completed |
NCT00986154 -
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
|
Phase 3 | |
| Terminated |
NCT00662688 -
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT00260988 -
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
|
Phase 2/Phase 3 | |
| Terminated |
NCT00031837 -
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03877770 -
DVT After Cardiac Procedure
|
||
| Completed |
NCT00024297 -
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
|
N/A | |
| Recruiting |
NCT06118957 -
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
|
Phase 2 |